Regional Variation in Deescalated Therapy in Older Adults With Early-Stage Breast Cancer
In this retrospective cross-sectional study of women aged 70 years or older diagnosed with T1N0 HR+/ERBB2- breast cancer, region/HSA contributed more to the variation in deescalated therapy use than patient factors. Unexplained variation may be attributed to unmeasured characteristics, such as multidisciplinary environment and patient preference. Decision support efforts to address overtreatment should target regions with low rates of evidence-based deescalation.
Authors
- Elizabeth A. Mittendorf (ORCID: https://orcid.org/0000-0002-9762-8536)
- Tari A. King (ORCID: https://orcid.org/0000-0003-3602-2351)
- Mara A. Schonberg (ORCID: https://orcid.org/0000-0001-5162-5922)
- Rachel A. Freedman (ORCID: https://orcid.org/0000-0003-0460-674X)
- Tanujit Dey (ORCID: https://orcid.org/0000-0001-5559-211X)
- Eliza H. Lorentzen
- Yu-Jen Chen (ORCID: https://orcid.org/0000-0001-9794-8938)
- Christina A. Minami
Institutions
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.41152
- Citations
- 4
- Primary Topic
- Global Cancer Incidence and Screening
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- California Department of Public Health
- University of Southern California
- National Institutes of Health
- Centers for Disease Control and Prevention
- University of California, San Francisco
- National Cancer Institute